Journal
CHEMICAL COMMUNICATIONS
Volume 58, Issue 95, Pages 13250-13253Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d2cc05278d
Keywords
-
Categories
Funding
- National Key Research and Development Program of China [2020YFA0908000]
- Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine [ZYYCXTD-C-202002]
- National Key R&D Program of China Key projects for international cooperation on science, technology and innovation [2020YFE0205100]
- CACMS Innovation Fund [CI2021A05101, CI2021A05104]
- Fundamental Research Funds for the Central public welfare research institutes [ZZ15-YQ-062]
- National Natural Science Foundation of China [82074098, 81841001, 82274182]
Ask authors/readers for more resources
Oridonin, derived from traditional Chinese medicine, is identified as a novel senolytic that may activate ROS-p38 signaling and induce apoptosis in senescent cells.
Most of the known senolytics are anti-cancer drugs or their derivative molecules. However, senolytics derived from the active ingredients of traditional Chinese medicine (TCM) are rarely reported. Here, we identified oridonin as a novel senolytic and further revealed that it might target a class of glutathione S-transferases to activate ROS-p38 signaling and induce apoptosis in senescent cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
